Staphylococcal Lysate
ImmLab´s solution: A Therapeutic Staphylococcal Lysate (SL) is prepared by lysis of S. aureus culture with a polyvalent bacteriophage. Staphylococcal phages belong mostly to the Siphoviridae family, e.g., phages with double-stranded linear DNA and with long noncontractile tails. SL is a complex of antigenic components of ribosomal, cytoplasmic, nuclear, cell wall, and membranous origin of the staphylococcal cell.
Our Products
After more than seventeen years of research ImmLab has novel technological inventions for the prevention and treatment of staphylococcal infections in humans and animals. With its patented technology, ImmLab is able to develop new products in reaction to actual epidemiological situation due to emerging resistant bacterial strains.
- Human vaccines
- Animal vaccines
- Vaccines for companion animals
Animal Health
Bovine Mastitis
In the U.S.A. the S. aureus mastitis comprise a total of 10-12% of all clinical mastitis. It creates the yearly cost/loss of the $2 billion to the American dairy industry.
The Companion Animals
The MRSA is emerging on the companion animals (dogs, cats and horses) as well as on swine herds through the whole word.
Immunology Laboratories, Inc.
Stable, tested and effective staphylococcal vaccine
ImmLab products are staphylococcal-lysate-based vaccines for prevention and treatment of staphylococcal infections in humans, farm animals, and companion animals.
The Problem
Increasing emergence of antibiotic-resistant strains of staphylococci in the human and veterinary medicine marketplace will hamper chemotherapeutic treatments of these infections. New antibiotics which will efficiently kill these antibiotic-resistant strains will apparently not be readily available in the near future.
Our Technology
ImmLab has novel technological inventions for the prevention and treatment of staphylococcal infections in humans and animals.
ImmLab has substantially completed the preclinical stage for human and small animals products. In the field of dairy staphylococcal mastitis the clinical studies have already started.
Contact us
ImmLab is also interested in creating a partnering, merge or acquisition relationship.
Patents
In ImmLab's pipeline are ST398 MRSA human and porcine vaccines, as well as several other patents.